{"id":"transdermal-fentanyl-matrix-gabapentin","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Somnolence"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Respiratory depression"}]},"_chembl":{"chemblId":"CHEMBL940","moleculeType":"Small molecule","molecularWeight":"171.24"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Transdermal fentanyl provides sustained opioid analgesia by activating mu-opioid receptors in the central and peripheral nervous system. Gabapentin reduces neuropathic pain by binding to the alpha-2-delta subunit of voltage-gated calcium channels, decreasing excitatory neurotransmitter release. The combination targets both opioid-responsive and neuropathic pain pathways for enhanced pain control.","oneSentence":"This combination uses fentanyl (an opioid mu-receptor agonist) delivered transdermally and gabapentin (a gabapentinoid that modulates calcium channels) to provide synergistic analgesia for chronic pain.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:13:40.103Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic pain management (specific indication not clearly defined in available literature)"}]},"trialDetails":[{"nctId":"NCT01127100","phase":"PHASE4","title":"Gabapentin Versus Transdermal Fentanyl Matrix for Chronic Neuropathic Pain","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2010-05","conditions":"Neuropathic Pain, Spinal Stenosis","enrollment":108}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"transdermal fentanyl matrix, gabapentin","genericName":"transdermal fentanyl matrix, gabapentin","companyName":"Seoul National University Hospital","companyId":"seoul-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses fentanyl (an opioid mu-receptor agonist) delivered transdermally and gabapentin (a gabapentinoid that modulates calcium channels) to provide synergistic analgesia for chronic pain. Used for Chronic pain management (specific indication not clearly defined in available literature).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}